WO2016152846A1 - 概日リズム改善用組成物 - Google Patents
概日リズム改善用組成物 Download PDFInfo
- Publication number
- WO2016152846A1 WO2016152846A1 PCT/JP2016/058963 JP2016058963W WO2016152846A1 WO 2016152846 A1 WO2016152846 A1 WO 2016152846A1 JP 2016058963 W JP2016058963 W JP 2016058963W WO 2016152846 A1 WO2016152846 A1 WO 2016152846A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- circadian rhythm
- composition
- improving
- rhythm
- gene
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a composition for improving circadian rhythm. Specifically, the present invention relates to a composition for improving circadian rhythm, which contains a lignan compound and is based on amplifying the amplitude of the periodic expression level of a clock gene.
- rhythms that exhibit a periodicity of almost 24 hours are called circadian rhythms (circadian rhythms).
- Biological activities and physiological phenomena having a circadian rhythm include sleep / wakefulness, blood pressure fluctuation, body temperature fluctuation, and eating behavior.
- All the cells that make up the body have a mechanism that oscillates circadian rhythm.
- This circadian rhythm oscillation mechanism is based on a change in the expression level of a plurality of gene groups called clock genes in a 24-hour cycle.
- clock genes By showing the circadian rhythm while each cell is synchronized, circadian rhythms of biological activities and physiological phenomena are further generated at the tissue level, organ level, and individual level.
- indices defining the rhythmicity of clock gene expression there are a cycle length (length of one cycle, approximately 24 hours), a phase (peak time of expression), and an amplitude (variation width of the expression level).
- the clock gene has a large change in gene expression level, that is, amplitude, between day and night, and this is repeated in a cycle of 24 hours, thereby achieving a certain behavior of the individual day and night.
- the circadian rhythm of biological activity is disturbed by modulation of one or more of the cycle length, phase, and amplitude.
- Physical disorders due to circadian rhythm disturbances and associated diseases include sleep disorders, autonomic dysfunction, endocrine disorders, and lifestyle-related diseases.
- Non-Patent Documents 1 to 3 Animal deficient in clock genes such as Bmal and CLOCK are prematurely aged. It has been found to be. And at the cellular level, it has been shown that the control of the clock oscillation mechanism breaks down with aging, and the flattening of circadian rhythm amplitude is observed especially in senescent cells, and this is related to aging of individuals. Has been reported.
- Such a circadian rhythm adjustment composition that can improve the modulation of the circadian rhythm, particularly a circadian rhythm adjustment composition that can amplify the circadian rhythm amplitude is desired.
- Such a circadian rhythm adjustment composition improves sleep disorders such as fragmentation of sleep and early awakening, and is useful for improving the physical condition of sleepiness, depth of sleep, and awakening of a person who feels fatigue on a daily basis.
- circadian rhythm adjusting agent focusing on the secretion rhythm of melatonin
- circadian rhythm regulators that focus on circadian rhythms of clock gene expression are circadian rhythm regulators that contain plant alkaloids as active ingredients, and the cycle length of circadian rhythms of the expression of clock gene Bmal 1 That regulates the expression of the rhythmic bacteria (Patent Document 2), which is a circadian rhythm adjusting agent containing a fermented lactic acid bacterium as an active ingredient, and that can increase the expression level of the clock genes Rev-erb ⁇ and PPAR ⁇ (Patent Document 3)
- a circadian rhythm regulator comprising lactic acid bacteria as an active ingredient, which can regulate the phase of expression of clock genes Per 1, Per 2, and Bmal 1 (Patent Document 4), flavonoids and the like as active ingredients
- circadian rhythm adjusting agent that can regulate the phase of expression of clock genes Per 1, Per 2, and Bmal 1
- Non-Patent Documents 4 and 5 show that caffeine has an action of amplifying circadian rhythm amplitude and an action of extending the period. However, caffeine has safety issues when overdose.
- An object of the present invention is to provide a composition for improving circadian rhythm that can be safely ingested over a long period of time, particularly a composition for adjusting circadian rhythm that can amplify the amplitude of circadian rhythm.
- the present inventors have found that the lignan compounds contained in sesame, which is a food with abundant food experience, have an action of amplifying the amplitude of the expression rhythm of the clock gene. I found it.
- a composition for improving circadian rhythm comprising at least one lignan compound.
- Composition. [7] The composition for improving circadian rhythm according to any one of [1] to [4], for improving sleep, depth of sleep and waking up.
- a method for producing a composition having a circadian rhythm improving effect comprising a step of blending one or more lignan compounds.
- the lignan compound is sesamin, episesamin, sesamorin, sesamol, sesaminol, or a glycoside or metabolite thereof, or a mixture of two or more thereof.
- Use of one or more lignan compounds in the production of a composition having a circadian rhythm improving action is sesamin, episesamin, sesamorin, sesamol, sesaminol or a glycoside or metabolite thereof or a mixture of two or more thereof.
- the composition for improving circadian rhythm of the present invention can improve the circadian rhythm by amplifying the amplitude of the expression rhythm of the clock gene by including one or more lignan compounds.
- the composition for improving circadian rhythm of the present invention effectively prevents, alleviates, or treats circadian rhythm disorders, particularly circadian rhythm disorders associated with aging, based on flattening of the amplitude of the expression rhythm of clock genes. And improve sleep, depth of sleep, and awakening.
- FIG. 1 shows a model diagram of the expression cycle of a clock gene.
- FIG. 4 shows the effect on the amplitude of the expression rhythm of the Per 2 gene when sesamin, episesamin, and sesaminol are added to a fetal fibroblast cell line derived from Per 2 :: LUC knock-in mouse.
- the circadian rhythm improving composition of the present invention contains one or more lignan compounds.
- lignan compound used in the present invention sesamin, sesaminol, episesamin, episesaminol, sesamolin, 2- (3,4-methylenedioxyphenyl) -6- (3-methoxy-4-hydroxyphenyl) -3,7-dioxabicyclo [3,3,0] octane, 2,6-bis- (3-methoxy-4-hydroxyphenyl) -3,7-dioxa Bicyclo [3,3,0] octane, 2- (3,4-methylenedioxyphenyl) -6- (3-methoxy-4-hydroxyphenoxy) -3,7-dioxabicyclo [3, 3, 0]
- Examples include octane and the like, and metabolites or glycosides thereof, and these can be used alone or in combination. For the purposes of the
- the above lignan compound is not limited in its form or production method.
- extracted from sesame oil by a known method for example, extraction by adding hot methanol to sesame oil, removing methanol and then adding acetone to the residue (described in JP-A-4-9331)
- Extract or purified product containing a high amount of lignan compound can also be used.
- a lignan compound can also be obtained by synthesis.
- sesamin and episesamin can be synthesized by the method of Beroza et al. (J. Am. Chem. Soc., (78, 1242 (1956)), and pinoresinol is synthesized by the method of Freundenberg et al. (Chem. Ber. , 86, 1157 (1953)), syringaresinol can be synthesized by the method of Freundenberg et al. (Chem. Ber., 88, 16 (1955)).
- the degree of concentration depends on the type of lignan compound and the circadian rhythm to be blended. What is necessary is just to set suitably with the form of the composition for improvement.
- a lignan compound concentrate that is concentrated so that the total amount of the lignan compound is 1% by weight or more.
- the total content of lignan compounds in the lignan compound concentrate is preferably 20% by weight or more, more preferably 50% by weight or more, more preferably 70% by weight or more, and 90% by weight. The above is most preferable.
- composition for improving circadian rhythm of the present invention contains one or more lignan compounds
- the circadian rhythm can be improved by amplifying the amplitude of the expression rhythm of one or more clock genes.
- Clock genes are a group of genes that act to regulate circadian rhythm. When these genes have mutations, they are defined as genes that affect behavioral rhythms (Ishida, 2009, Biochemistry, Vol. 81). , No. 2, pp. 75-83). Examples of clock genes include the Period gene, Bmal gene, Clock gene, Cryptochrome gene and the like.
- the circadian rhythm improving agent of the present invention can preferably amplify the amplitude of one or more expression rhythms of a gene belonging to the Period gene family and a gene belonging to the Cryptochrome gene family, and more preferably, PeriodPer1 (Per 1) Amplifying the amplitude of one or more expression rhythms of genes, Period ⁇ 2 (Per 2) gene, Period 3 (Per3) gene, Cryptochrome 1 (Cry 1) gene, Cryptochrome 2 (Cry 2) gene it can.
- the expression rhythm of the clock gene is a periodic fluctuation in the expression level observed when a change in the expression level of the clock gene is monitored over time.
- FIG. 1 shows a model diagram of a clock gene expression cycle.
- a rhythmic index of the expression rhythm of the clock gene the cycle length (length of one cycle, approximately 24 hours), phase (peak position of expression indicated by peak time of expression), amplitude (variation of expression level) Width).
- the amplification of the clock gene expression rhythm with the circadian rhythm improving composition of the present invention means the state before using the circadian rhythm improving composition of the present invention or the circadian rhythm improving composition of the present invention.
- the circadian rhythm indicated by the metabolism and secretion of substances in each cell is brought close to normal, or the circadian rhythm indicated by the metabolism and secretion of substances in each tissue is brought closer to normal or restored.
- the composition for improving circadian rhythm of the present invention can amplify the amplitude of the clock gene expression rhythm, and therefore, for prevention, alleviation, or treatment of circadian rhythm disorders based on the flattening of the clock gene expression amplitude. It can be particularly preferably used.
- Circadian rhythm disorders based on amplitude flattening of clock gene expression include sleep disturbance, behavioral day / night reversal, and body temperature rhythm amplitude flattening.
- Circadian rhythm disorders based on the flattening of the amplitude of clock gene expression include circadian rhythm disorders that occur with aging, problems of falling asleep, depth of sleep, and awakening, but are not limited to this. Absent.
- composition of the present invention can be provided in the form of an agent as an example, but is not limited to this form.
- the agent can be provided as a composition as it is or as a composition containing the agent.
- Such compositions include, but are not limited to, pharmaceuticals (pharmaceutical compositions), food and beverage compositions (beverages, foods, etc.), cosmetics (cosmetic compositions), and the like.
- pharmaceuticals pharmaceutical compositions
- food and beverage compositions beverages, foods, etc.
- cosmetics cosmetic compositions
- Non-limiting examples of food compositions include functional foods, health supplements, functional nutritional foods, special purpose foods, foods for specified health use, dietary supplements, dietary foods, health foods, supplements and the like.
- the composition for improving circadian rhythm of the present invention can be applied to any therapeutic use (medical use) or non-therapeutic use (non-medical use). Specifically, it does not belong to pharmaceuticals, quasi-drugs, cosmetics, etc. or the Pharmaceutical Affairs Law, but prevents, alleviates, or treats circadian rhythm disorders based on the flattening of clock gene expression amplitude. Use as an explicitly or implicitly appealing composition. It can also be a composition displaying their efficacy, for example, “improving sleep disorders”, “improving sleep quality”, “improving sleep”, “improving reversal of day and night”, “flattening of temperature rhythm amplitude Indications related to “reform”, “improvement of awakening”, “recovery from fatigue”, and the like can be attached. As a specific example, a display such as “useful for improving the physical condition of sleep, depth of sleep, and awakening of a person who feels tired on a daily basis” based on the circadian rhythm improvement effect can be given.
- the expression level of the clock gene when using the circadian rhythm improving composition of the present invention can be analyzed using any method known to those skilled in the art. For example, methods such as Northern blotting analysis using an arbitrary sequence in the target clock gene sequence as a probe, real-time RT-PCR analysis, and expression level analysis using a DNA microarray can be preferably used. Any sample can be used as a sample for gene expression analysis as long as it contains cells. For example, hair containing hair follicle cells, biopsy such as skin, blood, saliva, etc. can be used. .
- composition for improving circadian rhythm of the present invention as long as it does not impair the effect of the lignan compound, that is, an undesirable interaction is not caused by blending with the lignan compound, a mineral; vitamin E, Vitamins such as vitamin C and vitamin A; nutritional ingredients; fragrances; other additives such as pigments can be mixed.
- compositions for improving circadian rhythm of the present invention are not particularly limited, and liquids such as liquids, suspensions, and emulsions; semisolid agents such as pastes; granules, powders, powders, tablets, capsules It can be formulated in the form of agents (including soft capsules and hard capsules).
- the composition for improving circadian rhythm of the present invention can also be used as an internal composition of a capsule.
- the content of the lignan compound as an active ingredient can be appropriately determined in consideration of the effect.
- the circadian rhythm improving composition of the present invention has a total content of lignan compound of 0.001 to 90% by weight, 0.01 to 50% by weight, or It can be contained in an amount of 0.1 to 10% by weight.
- the dosage and administration form of the composition for improving circadian rhythm of the present invention can be appropriately selected in consideration of the age, weight, condition, etc. of the subject.
- sesamin when sesamin is selected as a lignan compound and is orally administered to humans (adults), sesamin is generally 1 to 200 mg, preferably 3 to 100 mg, more preferably about 5 to 50 mg per day. As such, it may be administered continuously at a rate of about once or twice a day and 5 or more times a week.
- the present invention also relates to a method for producing a composition having a circadian rhythm improving action, which comprises a step of blending one or more lignan compounds.
- compositions of the present invention are not particularly limited, and in addition to pharmaceutical compositions such as pharmaceuticals and quasi-drugs, it does not belong to these under the Pharmaceutical Affairs Law, but in order to give a sharper lifestyle of day and night, As with pharmaceuticals and quasi-drugs, circadian rhythm improvement / prevention / therapeutic effects, sleepiness, depth of sleep, improvement of waking wakes are explicitly added or implied. Also included are appealing compositions.
- Such compositions also include food compositions, and non-limiting examples include functional foods, health supplements, functional nutritional foods, special purpose foods, foods for specified health use, dietary supplements, dietary foods, health foods. , Supplements and the like.
- the dosage form and shape of the composition are not particularly limited, but liquids such as liquids, suspensions, and emulsions; semisolid agents such as pastes; granules, powders, powders, tablets, capsules (soft capsules, Including a hard capsule) or an internal composition of the capsule.
- the composition produced by the method of the present invention has a total content of lignan compound of 0.001 to 90% by weight, 0.01 to 50% by weight, or It can be contained in an amount of 0.1 to 10% by weight.
- compositions can be prepared by adding an acceptable carrier or excipient to one or more lignan compounds.
- the carrier include water, physiological saline, edible oil, ethanol, propylene glycol, glycerin and the like.
- excipients include glucose, sucrose, lactose, dextrin, cyclodextrin, xanthan gum, guar gum, gum arabic, tragacanth gum, gellan gum, locust bean gum, carrageenan, pectin, agar and the like.
- emulsifiers such as tonicity agents (isotonic agents), buffers, solubilizers, preservatives, stabilizers, antioxidants, and the like that are generally used in formulation can be appropriately blended.
- minerals such as vitamin E, vitamin C, and vitamin A
- nutrition such as vitamin E, vitamin C, and vitamin A
- Example 1 ⁇ Effects of lignan compounds on the expression rhythm of Per 2 gene in cultured cells>
- Per2 :: LUC knock-in mouse-derived fetal fibroblast cell line was used as the cell line.
- the Per2 :: LUC knock-in mouse is a mouse in which a luciferase gene as a reporter is introduced downstream of the promoter region of the clock gene Per2. Therefore, in the Per 2 :: LUC knock-in mouse-derived fetal fibroblast cell line, the luciferase gene is expressed in accordance with the periodic expression of the clock gene.
- Per 2 LUC knock-in mouse embryonic fibroblasts cultured in a medium containing luciferase, which is a substrate for luciferase, periodically chemiluminescent, so by monitoring the luminescence, expression of the clock gene Per 2 It becomes possible to evaluate the rhythm.
- test substance sesamin was confirmed to increase in amplitude in a dose-dependent manner with respect to the circadian rhythm of Per 2 gene expression, particularly in the range of 3 to 50 ⁇ M.
- Example 2 ⁇ Influence of lignan compounds on the expression rhythm of Per 2 gene in vivo> As the animal, the Per 2 :: LUC knock-in mouse described in Example 1 was used. Since this mouse periodically expresses the reporter gene luciferin downstream of the clock gene, chemiluminescence occurs when the luminescent substrate luciferin is administered from the outside. Therefore, the expression of clock gene Per2 can be monitored over time in vivo.
- Example 3 ⁇ Effects of lignan compounds on the expression rhythm of Per 2 gene in cultured cells 2> The test method was the same as in Example 1 above. As test substances, 10 ⁇ M each of sesamin, episesamin, and sesaminol was added, and the effects were evaluated. The results are shown in FIG. As a result, it was confirmed that sesamin, episesamin, and sesaminol all increase the amplitude of Per2 gene expression.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
[1]
1種以上のリグナン類化合物を含む、概日リズム改善用組成物。
[2]
リグナン類化合物が、セサミン、エピセサミン、セサモリン、セサモール、セサミノール若しくはこれらの配糖体若しくは代謝物又は2つ以上のこれらの混合物である、[1]に記載の概日リズム改善用組成物。
[3]
1つ以上の時計遺伝子の発現リズムの振幅を増幅する、[1]又は[2]に記載の概日リズム改善用組成物。
[4]
時計遺伝子がPer 2又はCry1遺伝子である、[3]に記載の概日リズム改善用組成物。
[5]
加齢に伴う概日リズム障害の予防、緩和、又は治療のための、[1]~[4]のいずれかに記載の概日リズム改善用組成物。
[6]
加齢に伴う概日リズム障害が、加齢に伴って生じる睡眠障害、行動の昼夜逆転、及び体温リズムの振幅の平坦化からなる群より選択される、[5]に記載の概日リズム改善用組成物。
[7]
寝つき、眠りの深さ、寝覚めの改善のための、[1]~[4]のいずれかに記載の概日リズム改善用組成物。
[8]
前記成物が剤である、[1]~[7]のいずれかに記載の概日リズム改善用組成物。
[9]
1種以上のリグナン類化合物を配合する工程を含むことを特徴とする、概日リズム改善作用を有する組成物の製造方法。
[10]
リグナン類化合物が、セサミン、エピセサミン、セサモリン、セサモール、セサミノール若しくはこれらの配糖体若しくは代謝物又は2つ以上のこれらの混合物である、[9]に記載の方法。
[11]
概日リズム改善作用を有する組成物の製造における、1種以上のリグナン類化合物の使用。
[12]
リグナン類化合物が、セサミン、エピセサミン、セサモリン、セサモール、セサミノール若しくはこれらの配糖体若しくは代謝物又は2つ以上のこれらの混合物である、[11]に記載の使用。
本発明の概日リズム改善用組成物は、1種以上のリグナン類化合物を含む。本発明で使用するリグナン類化合物としては、本発明で使用するリグナン類化合物としては、セサミン、セサミノール、エピセサミン、エピセサミノール、セサモリン、 2-(3,4-メチレンジオキシフェニル)-6-(3-メトキシ-4-ヒドロキシフェニル)-3,7-ジオキサビシクロ [3,3,0]オクタン、 2,6-ビス-(3-メトキシ-4-ヒドロキシフェニル)-3,7-ジオキサビシクロ[3,3,0]オクタン、2-(3, 4-メチレンジオキシフェニル)-6-(3-メトキシ-4-ヒドロキシフェノキシ)-3,7-ジオキサビシクロ[3, 3, 0]オクタン等、及びこれらの代謝物又は配糖体を挙げることができ、これらを単独で、又は混合して使用することができる。本発明の目的のためには、セサミン、エピセサミン、セサモリン、セサモール、セサミノール若しくはこれらの配糖体若しくは代謝物又は2つ以上のこれらの混合物を好適に用いることができる。
本発明の概日リズム改善用組成物は、1種以上のリグナン類化合物を含むことにより、1以上の時計遺伝子の発現リズムの振幅を増幅し、概日リズムを改善することができる。
本発明は、1種以上のリグナン類化合物を配合する工程を含むことを特徴とする、概日リズム改善作用を有する組成物の製造方法にも関する。
実施例1
<培養細胞におけるPer 2遺伝子の発現リズムに対するリグナン類化合物の影響>
細胞株はPer2::LUCノックインマウス由来胎児繊維芽細胞株を用いた。Per2::LUCノックインマウスとは、時計遺伝子Per 2のプロモーター領域下流にレポーターであるルシフェラーゼ遺伝子が導入されているマウスである。したがって、Per 2::LUCノックインマウス由来胎児繊維芽細胞株では、時計遺伝子の周期的な発現に合わせてルシフェラーゼ遺伝子が発現する。Per 2::LUCノックインマウス由来胎児繊維芽細胞をルシフェラーゼの基質であるルシフェリン含有培地にて培養すると、細胞は周期的に化学発光するため、その発光をモニターすることで、時計遺伝子Per 2の発現リズムを評価することが可能になる。
<in vivoにおけるPer 2遺伝子の発現リズムに対するリグナン類化合物の影響>
動物は実施例1で記載したPer 2::LUCノックインマウスを用いた。本マウスは時計遺伝子下流のレポーター遺伝子ルシフェリンが周期的に発現することから、外部から発光基質ルシフェリンを投与すると化学発光する。このためin vivoで時計遺伝子Per 2の発現を経時的にモニタリングすることが出来る。
<培養細胞におけるPer 2遺伝子の発現リズムに対するリグナン類化合物の影響2>
試験方法は上述の実施例1と同様に行った。被験物質として、セサミン、エピセサミン、セサミノールをそれぞれ10μM添加し、その影響を評価した。結果を図4に示す。この結果、セサミン、エピセサミン、セサミノールはいずれもPer2遺伝子発現の振幅を高めることが確認された。
Claims (12)
- 1種以上のリグナン類化合物を含む、概日リズム改善用組成物。
- リグナン類化合物が、セサミン、エピセサミン、セサモリン、セサモール、セサミノール若しくはこれらの配糖体若しくは代謝物又は2つ以上のこれらの混合物である、請求項1に記載の概日リズム改善用組成物。
- 1つ以上の時計遺伝子の発現リズムの振幅を増幅する、請求項1又は2に記載の概日リズム改善用組成物。
- 時計遺伝子がPer 2又はCry1遺伝子である、請求項3に記載の概日リズム改善用組成物。
- 加齢に伴う概日リズム障害の予防、緩和、又は治療のための、請求項1~4のいずれか一項に記載の概日リズム改善用組成物。
- 加齢に伴う概日リズム障害が、加齢に伴って生じる睡眠障害、行動の昼夜逆転、及び体温リズムの振幅の平坦化からなる群より選択される、請求項5に記載の概日リズム改善用組成物。
- 寝つき、眠りの深さ、寝覚めの改善のための、請求項1~4のいずれかに記載の概日リズム改善用組成物。
- 前記成物が剤である、請求項1~7のいずれか一項記載の概日リズム改善用組成物。
- 1種以上のリグナン類化合物を配合する工程を含むことを特徴とする、概日リズム改善作用を有する組成物の製造方法。
- リグナン類化合物が、セサミン、エピセサミン、セサモリン、セサモール、セサミノール若しくはこれらの配糖体若しくは代謝物又は2つ以上のこれらの混合物である、請求項9に記載の方法。
- 概日リズム改善作用を有する組成物の製造における、1種以上のリグナン類化合物の使用。
- リグナン類化合物が、セサミン、エピセサミン、セサモリン、セサモール、セサミノール若しくはこれらの配糖体若しくは代謝物又は2つ以上のこれらの混合物である、請求項11に記載の使用。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017508352A JP6779861B2 (ja) | 2015-03-23 | 2016-03-22 | 概日リズム改善用組成物 |
US15/560,277 US20180071248A1 (en) | 2015-03-23 | 2016-03-22 | Composition for improving circadian rhythm |
CN201680017799.2A CN107405329B (zh) | 2015-03-23 | 2016-03-22 | 昼夜节律改善用组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015059753 | 2015-03-23 | ||
JP2015-059753 | 2015-03-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016152846A1 true WO2016152846A1 (ja) | 2016-09-29 |
Family
ID=56978280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/058963 WO2016152846A1 (ja) | 2015-03-23 | 2016-03-22 | 概日リズム改善用組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20180071248A1 (ja) |
JP (1) | JP6779861B2 (ja) |
CN (1) | CN107405329B (ja) |
TW (1) | TWI666018B (ja) |
WO (1) | WO2016152846A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7079931B2 (ja) * | 2018-05-10 | 2022-06-03 | 淳三 亀井 | セサミノールとシクロデキストリンとの包接複合体及びその製造方法 |
WO2021065664A1 (ja) * | 2019-10-04 | 2021-04-08 | サントリーホールディングス株式会社 | 生活活動量の維持、低下予防、低下抑制又は改善用組成物 |
CN113480555B (zh) * | 2021-08-11 | 2022-10-18 | 西北农林科技大学 | 一种含3,7-二氧杂双环[3,3,0]辛烷结构的木脂素类化合物及其制备方法和应用 |
CN114716404A (zh) * | 2022-03-03 | 2022-07-08 | 大连医科大学 | 一类细胞色素p450 46a1酶抑制剂及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000143546A (ja) * | 1998-11-16 | 2000-05-23 | Hiroshi Wada | メラトニンの酸化分解抑制剤 |
JP2010285427A (ja) * | 2009-05-12 | 2010-12-24 | Suntory Holdings Ltd | 睡眠障害改善剤 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080275110A1 (en) * | 2004-12-28 | 2008-11-06 | Yoshiko Ono | Sesamin/Episesamin Compositions |
KR101451438B1 (ko) * | 2006-03-15 | 2014-10-15 | 산토리 홀딩스 가부시키가이샤 | 리보플라빈과 세사민류를 함유하는 조성물 |
US9408803B2 (en) * | 2006-03-31 | 2016-08-09 | Suntory Holdings Limited | Compositions containing lignan-class compounds |
CN101361840A (zh) * | 2007-08-12 | 2009-02-11 | 文山壮族苗族自治州三七科学技术研究所 | 一种改善睡眠的保健食品胶囊制剂 |
AU2008301694B2 (en) * | 2007-09-19 | 2013-07-18 | Suntory Holdings Limited | Compositions Containing Sesamin-Class Compound(s) and Arachidonic Acid Class Compound(s) |
JP5450075B2 (ja) * | 2007-09-19 | 2014-03-26 | サントリーホールディングス株式会社 | セサミン類とビタミンb1類とを配合した組成物 |
JP5276316B2 (ja) * | 2007-12-28 | 2013-08-28 | サントリーホールディングス株式会社 | セサミン類及びケルセチン配糖体を含有する組成物 |
JP6157463B2 (ja) * | 2012-06-14 | 2017-07-05 | サントリーホールディングス株式会社 | セサミン類とγ−オリザノールと米胚芽油とを含有する組成物 |
-
2016
- 2016-03-22 CN CN201680017799.2A patent/CN107405329B/zh active Active
- 2016-03-22 TW TW105109131A patent/TWI666018B/zh active
- 2016-03-22 JP JP2017508352A patent/JP6779861B2/ja active Active
- 2016-03-22 US US15/560,277 patent/US20180071248A1/en not_active Abandoned
- 2016-03-22 WO PCT/JP2016/058963 patent/WO2016152846A1/ja active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000143546A (ja) * | 1998-11-16 | 2000-05-23 | Hiroshi Wada | メラトニンの酸化分解抑制剤 |
JP2010285427A (ja) * | 2009-05-12 | 2010-12-24 | Suntory Holdings Ltd | 睡眠障害改善剤 |
Non-Patent Citations (1)
Title |
---|
YUKI YAMAUCHI ET AL.: "Mouse ni Okeru Amani Lignan no Gaijitsu Rhythm e Ataeru Eikyo", JAPANESE SOCIETY FOR FOOD FACTORS GAKUJUTSU SHUKAI KOEN YOSHISHU, vol. 19th, 2014, pages 49 * |
Also Published As
Publication number | Publication date |
---|---|
JP6779861B2 (ja) | 2020-11-04 |
TWI666018B (zh) | 2019-07-21 |
US20180071248A1 (en) | 2018-03-15 |
TW201642852A (zh) | 2016-12-16 |
JPWO2016152846A1 (ja) | 2018-01-11 |
CN107405329B (zh) | 2021-04-09 |
CN107405329A (zh) | 2017-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100150890A1 (en) | Medicinal composition, food or drink having effect of enhancing sympathetic nervous activity | |
JP6779861B2 (ja) | 概日リズム改善用組成物 | |
EP2143719A1 (en) | Pharmaceutical composition, food or beverage capable of enhancing sympathetic nerve activity | |
CN107890476B (zh) | 用于使时钟基因的表达变化的组合物 | |
JP6516259B2 (ja) | 睡眠改善剤 | |
JP2011241209A (ja) | ガングリオシド又はその誘導体を有効成分とするbdnf産生促進剤並びにそれを含有する医薬品、飲食品及び飼料 | |
JP2017137296A (ja) | アストロサイトのグルコース代謝活性化剤 | |
WO2021230145A1 (ja) | ニコチンアミドアデニンジヌクレオチド(nad)濃度上昇剤 | |
JP6045369B2 (ja) | 一酸化窒素産生抑制剤 | |
KR101907151B1 (ko) | 디아세틸을 포함하는, 암 줄기세포 성장 억제용 조성물 | |
WO2019156213A1 (ja) | グリセロール放出促進剤 | |
KR101769972B1 (ko) | 한약재 추출물(yj05)을 함유하는 불면증 개선, 예방 또는 치료용 조성물 | |
JP2020143008A (ja) | 新規褐色脂肪細胞分化誘導剤 | |
JP2020045296A (ja) | M.aerilataを有効成分とする皮膚外用組成物 | |
JP6417120B2 (ja) | 経口紫外線抵抗性向上剤 | |
JP2005187341A (ja) | プロスタグランジンe2産生抑制剤及び抗炎症剤 | |
JP2018138524A (ja) | 時計遺伝子発現調整剤、及びこれを含有する概日リズム調整剤 | |
JP6993819B2 (ja) | 概日リズム調節剤 | |
WO2015029968A1 (ja) | 時計遺伝子の発現量調整剤 | |
KR101852054B1 (ko) | 시스-3-헥센알을 포함하는, 암 줄기세포 성장 억제용 조성물 | |
WO2017130638A1 (ja) | アストロサイトのグルコース代謝活性化剤 | |
JP2021052736A (ja) | 概日リズム調節剤 | |
JP2016124842A (ja) | 脂肪燃焼促進剤及び低体温改善剤 | |
JP2024000684A (ja) | 細胞多様性と複雑な組織構造を保持したがん組織の治療剤 | |
JP2013006809A (ja) | 新規イソフラボン化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16768749 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017508352 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15560277 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16768749 Country of ref document: EP Kind code of ref document: A1 |